Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer
Inivata, a leader in liquid biopsy, announces new data in support of its RaDaR assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Read More
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Marla Lipsyc-Sharf, MD Elza C. de Bruin, PhD Katheryn Santos, BS Robert McEwen, PhD Daniel Stetson, MS Ashka Patel, BS Gregory J. ... Read More
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.